Exicure, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a XCUR research report →
Range $12 – $12
Price Chart
About the company
Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets.
- CEO
- Jungsoo Kim
- IPO
- 2018
- Employees
- 1
- HQ
- Redwood City, CA, US
Get TickerSpark's AI analysis on XCUR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $6.88M
- P/E
- -0.82
- PEG
- 0.01
- P/S
- 0.00
- P/B
- 7.05
- EV/EBITDA
- -0.60
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -237.91%
- ROIC
- -93.88%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $-460,000-192.0%
- Op Income
- $-10,117,000
- Net Income
- $-4,946,000+49.0%
- EPS
- $-0.79+50.3%
- OCF Growth
- -194.0%
- FCF Growth
- -194.0%
- 52W High
- $9.48
- 52W Low
- $1.05
- 50D MA
- $1.34
- 200D MA
- $3.17
- Beta
- 3.63
- RSI (14)
- 35
- Avg Volume
- 401.24K
No earnings-call transcripts are available for XCUR yet.
- Free Float
- 28.1%
- Shares Outstanding
- 6.55M
- Float Shares
- 1.79M
of shares held by institutions
17 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Capital Management LLC | 43.11K | ▲ 10.13K |
| Vanguard Group Inc | 42.04K | 0 |
| Geode Capital Management, LLC | 31.25K | ▼ 5.66K |
| Jane Street Group, LLC | 29.54K | ▲ 29.54K |
| Citadel Advisors LLC | 14.92K | ▲ 14.92K |
| Vanguard Fiduciary Trust Co | 13.16K | 0 |
| Tower Research Capital LLC (Trc) | 4.07K | ▲ 3.58K |
| Ubs Group AG | 342 | ▼ 524 |
| Morgan Stanley | 143 | ▼ 15 |
| Sbi Securities Co., Ltd. | 43 | 0 |
| Blackrock, Inc. | 35 | ▼ 9.32K |
| Advisor Group Holdings, Inc. | 29 | 0 |
Held by 21 ETFs
Biggest fund positions in XCUR by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 8, 26 | Exicure HiTron Inc. | other | 117,441 |
| Jun 26, 26 | Exicure HiTron Inc. | other | 253,195 |
| Jun 24, 26 | Exicure HiTron Inc. | other | 123,456 |
| Jun 23, 26 | Exicure HiTron Inc. | other | 129,183 |
| Feb 16, 26 | Miller Josh | other | 8 |
| Jan 21, 26 | Exicure HiTron Inc. | sell | 258,367 |
| Jan 16, 26 | Exicure HiTron Inc. | sell | 734,747 |
| Jan 7, 26 | Exicure HiTron Inc. | sell | 741,272 |
| Dec 8, 25 | SANGSANGIN INVESTMENT & SECURITIES CO., LTD. | sell | 433,332 |
| Nov 16, 25 | Miller Josh | other | 7 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our XCUR coverage
Recent articles, reports, and earnings notes.
No research on XCUR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate XCUR report →Exicure Receives Nasdaq Extension to Regain Compliance with Stockholders' Equity Requirement
globenewswire.com · Sep 16
Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance
globenewswire.com · Aug 3
Exicure Announces Board and Committee Changes
globenewswire.com · Jun 30
Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement
globenewswire.com · Jun 10
Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement
globenewswire.com · Jun 10
Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q
globenewswire.com · Jun 1
Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)
globenewswire.com · Apr 22
Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)
globenewswire.com · Apr 22
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.